Line Ulvestad1, Georg Sager. 1. Klinisk farmakologisk avdeling, Universitetssykehuset Nord-Norge, 9038 Tromsø.
Abstract
BACKGROUND: Levels of cyclic guanosine 3',5'-monophosphate (cGMP) are elevated in plasma and urine from patients with some cardiovascular diseases and some types of cancer. MATERIALS AND METHODS: This paper is based on studies of cGMP as a biomarker. RESULTS AND INTERPRETATION: It is well documented that cGMP levels are elevated in plasma in patients with heart failure and various leukaemias and in urine from patients with gynaecological cancers. Because of great interindividual variation in levels, cGMP is less suitable in primary diagnostics, but appears to be a sensitive marker in individual follow up in some diseases.
BACKGROUND: Levels of cyclic guanosine 3',5'-monophosphate (cGMP) are elevated in plasma and urine from patients with some cardiovascular diseases and some types of cancer. MATERIALS AND METHODS: This paper is based on studies of cGMP as a biomarker. RESULTS AND INTERPRETATION: It is well documented that cGMP levels are elevated in plasma in patients with heart failure and various leukaemias and in urine from patients with gynaecological cancers. Because of great interindividual variation in levels, cGMP is less suitable in primary diagnostics, but appears to be a sensitive marker in individual follow up in some diseases.
Authors: Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt Journal: Cardiovasc Res Date: 2022-07-20 Impact factor: 13.081